Newswise — TAMPA, Fla. - March 05, 2013 – Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson’s disease, Huntington’s disease, multiple sclerosis, Alzheimer’s disease as well as brain and spinal cord injury.
Human umbilical cord blood provides a rich source of hematopoietic (blood) multipotent stem cells that can differentiate and give rise to all of the blood cell types.
“A single cord blood sample provides enough hematopoietic stem cells to provide short and long-term engraftment with a low incidence of graft-versus-host disease,” said Dr. Alison E. Willing, professor, Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida and an inventor on the patent. “The object of this newly patented process is a method for isolating and inducing pluripotent stem or progenitor cells into becoming neural or glial cells for use in stem cell transplantation procedures to treat neurodegenerative diseases as well as spinal cord and brain injuries.”
The cells can be provided by self-donors (autologous) or other-donors (allogeneic). Also, the umbilical cord blood sample may be fresh or frozen (cryopreserved).
According to Linda Kelley, PhD, chief scientific officer with Cryo-Cell International, a partner of Saneron-CCEL, “This novel patented process will facilitate the use of umbilical cord blood that is too often disposed of as medical waste. Now, umbilical cord blood can be used for the treatment of neurological conditions for which there are few alternatives.”
The newly patented procedure includes the process for the steps involved in separating the pluripotent stem and progenitor cells from a population of mononuclear cells obtained from umbilical cord blood using a magnetic separator and then expanding the cells while incubating them in a ‘growth factor medium.’ A differentiation agent is designed for helping the cells change their characteristics into a population of neural cells suitable for transplantation.
“Umbilical cord blood cells also provide an advantage in that they are easier to obtain than bone marrow cells,” said Nicole Kuzmin-Nichols, Saneron president and COO.
The researchers receiving the patent say that the patented process of retrieval, incubation and transplantation of cells derived from umbilical cord blood will allow for treating not only neurodegenerative diseases but also, because of their multipotent nature, they can potentially be used to treat heart attack and cardiovascular diseases.
About Saneron CCEL Therapeutics, Inc.Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases which lack adequate treatment options. Saneron, a University of South Florida spin-out company, is located at the Tampa Bay Technology Incubator. Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to its platform technology of umbilical cord blood and Sertoli cells.
About Cryo-Cell International, Inc. Cryo-Cell International, Inc. was founded in 1989. In 1992, it became the first private cord blood bank in the world to separate and store stem cells. Today, more than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members’ stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is compliant with Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP), and is ISO 9001:2008 certified and accredited by the American Association of Blood Banks. The company maintains a significant ownership stake in Saneron-CCEL, its research affiliate. Cryo-Cell is a publicly traded company, OTC: CCEL. For more information, visit www.cryo-cell.com.
For further information please contact:Saneron CCEL Therapeutics Inc.,Nicole Kuzmin-Nichols, MBA3802 Spectrum Blvd., Suite 112FTampa, FL 33612Phone: 813-977-7664[email protected]
Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.